The impact of ACAT1 inhibition extends to melanoma, where Avasimibe enhances the cytotoxic response from T cells in mouse models, concurrently resulting in a decrease in metastatic dissemination and tumour growth [138]. This evidence concerns the gene ACAT1 and neoplasm.